$1.25 Million in Sales Expected for Editas Medicine Inc (EDIT) This Quarter

Wall Street analysts expect Editas Medicine Inc (NASDAQ:EDIT) to report sales of $1.08 million for the current quarter, according to Zacks. Two analysts have issued estimates for Editas Medicine’s earnings, with estimates ranging from $900,000.00 to $1.25 million. Editas Medicine posted sales of $810,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 33.3%. The company is expected to announce its next earnings report on Monday, May 15th.

On average, analysts expect that Editas Medicine will report full year sales of $1.08 million for the current fiscal year, with estimates ranging from $3.6 million to $5 million. For the next fiscal year, analysts anticipate that the company will post sales of $4.3 million per share, with estimates ranging from $3.6 million to $5 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that cover Editas Medicine.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Tuesday, March 7th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by $0.48. Editas Medicine had a negative return on equity of 59.22% and a negative net margin of 1,184.46%. The company earned $0.90 million during the quarter, compared to analyst estimates of $1.11 million. During the same period in the prior year, the firm earned ($4.05) EPS.

Several analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a research note on Tuesday, March 28th. Chardan Capital assumed coverage on shares of Editas Medicine in a research note on Monday, March 27th. They issued a “buy” rating on the stock. Vetr upgraded shares of Editas Medicine from a “buy” rating to a “strong-buy” rating and set a $27.14 target price on the stock in a research note on Monday, March 20th. Cowen and Company reiterated a “buy” rating on shares of Editas Medicine in a research note on Wednesday, March 15th. Finally, JPMorgan Chase & Co. set a $32.00 target price on shares of Editas Medicine and gave the stock a “hold” rating in a research note on Wednesday, March 8th. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $27.79.

In other Editas Medicine news, CFO Andrew A. F. Hack sold 3,000 shares of the stock in a transaction that occurred on Wednesday, February 15th. The shares were sold at an average price of $19.20, for a total value of $57,600.00. Following the sale, the chief financial officer now directly owns 3,000 shares in the company, valued at approximately $57,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Alexandra Glucksmann sold 1,000 shares of the stock in a transaction that occurred on Wednesday, March 15th. The stock was sold at an average price of $26.41, for a total transaction of $26,410.00. Following the completion of the sale, the chief operating officer now owns 118,788 shares in the company, valued at $3,137,191.08. The disclosure for this sale can be found here. Insiders sold a total of 10,000 shares of company stock worth $207,490 over the last quarter.

Hedge funds have recently bought and sold shares of the stock. Barrett Asset Management LLC bought a new stake in Editas Medicine during the first quarter valued at $223,000. Fox Run Management L.L.C. bought a new stake in Editas Medicine during the first quarter valued at $272,000. Russell Investments Group Ltd. bought a new stake in Editas Medicine during the fourth quarter valued at $284,000. Victory Capital Management Inc. bought a new stake in Editas Medicine during the third quarter valued at $299,000. Finally, A.R.T. Advisors LLC bought a new stake in Editas Medicine during the fourth quarter valued at $417,000. Hedge funds and other institutional investors own 60.89% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.chaffeybreeze.com/2017/05/19/1-08-million-in-sales-expected-for-editas-medicine-inc-edit-this-quarter-updated-updated.html.

Shares of Editas Medicine (NASDAQ:EDIT) traded down 2.99% during mid-day trading on Friday, hitting $18.85. The company’s stock had a trading volume of 525,218 shares. The stock’s market cap is $675.58 million. The company has a 50-day moving average price of $21.22 and a 200-day moving average price of $18.38. Editas Medicine has a 1-year low of $12.43 and a 1-year high of $38.25.

Editas Medicine Company Profile

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

5 Day Chart for NASDAQ:EDIT

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Editas Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply